论文部分内容阅读
目的 探讨长期血透尿毒症患者中由于血清甲状旁腺激素（ＰＴＨ）水平升高所致重组人类促红细胞生成素（ｒＨｕＥＰＯ）疗效差的治疗。方法 用放免法、ＥＬＩＳＡ法分别测定对ｒＨｕＥＰＯ疗效差的Ｇ_２组和对ｒＨｕＥＰＯ有疗效的Ｇ_1；组患者血清ｒＨｕＥＰＯ和ＰＴＨ水平，并对Ｇ_２组中血清ＰＴＨ明显升高的５例患者口服罗钙全冲击治疗２月，观察其对ｒＨｕＥＰＯ疗效的影响。结果 Ｇ_１组和Ｇ_２组患者血ｒＨｕＥＰＯ水平无明显差异，但是ＰＴＨ Ｇ_2组比Ｇ_１组明显升高。Ｇ_２组中５例口服罗钙全冲击治疗２月后贫血有改善。结论 在血ＰＴＨ水平升高所致ｒＨｕＥＰＯ疗效差的长期血透尿毒症患者中，口服罗钙全冲击治疗能改善ｒＨｕＥＰＯ的疗效。
Objective To investigate the efficacy of recombinant human erythropoietin (rHuEPO) in patients with chronic hemodialysis due to elevated levels of serum parathyroid hormone (PTH). Methods The levels of rHuEPO and PTH in serum of G 2 patients with poor response to rHuEPO and those of patients with rHuEPO were determined by radioimmunoassay and ELISA respectively. Five patients with GOP elevated serum PTH Impact treatment in February to observe the effect of rHuEPO effect. Results There was no significant difference in blood rHuEPO levels between G_1 group and G_2 group, but PTH G_2 group was significantly higher than G_1 group. G 2 group, 5 cases of oral calcium full impact of treatment of anemia after 2 months to improve. Conclusion In long-term hemodialysis patients with poor efficacy of rHuEPO caused by elevated blood PTH levels, oral ropivacaine total impact treatment can improve the efficacy of rHuEPO.